The MenoLabs Difference

By 2025, one billion women will have experienced menopause. This transition can be life-disrupting, lasting from 4 to 14 years, with 33 or more symptoms. Women in the United States spend billions on hormone replacement therapy and other treatments with known risks to alleviate these symptoms. Additionally, the result of the menopausal transition is one that has a significant impact on the health and lives of women.

Even though a majority of US citizens will experience this transition, and it is one of the major health and well-being impacts in a woman’s life, the institutional funding mechanisms for research into this transition and how to support better health outcomes for women remain dramatically below the levels of many other health concerns.

Our efforts are to use Real World Evidence (RWE) to document symptoms, symptom triggers, and overall health and well-being inputs that may impact women and capture the impact of natural support supplements on these symptoms, using far larger sample sizes than traditional clinical studies.

By increasing our study population size and consistently adding more depth to symptom, health, and behavioral tracking we can inform strategies and behaviors for women to consider that suggest better quality of life outcomes in the immediate term, and improved transition through menopause.

By combining this overall research with specific retrospective analysis of MenoLabs natural formulas to support the menopausal transition, we can gather significant, robust data as to the efficacy of these natural supplements’ impacts on menopausal symptoms.

As industry and research leaders have discovered, RWE that is recorded contemporaneously outside of the confines of formal studies reveals novel statistical connections and effectively captures surprising relationships in behavior and outcomes that can better inform traditional formal studies. By leveraging current technology we can build robust data sets and complex models that reveal particular patterns, so that the limited research funding which is allocated to women’s midlife health can be most efficiently applied to yield better understanding of this transition and its impact on women’s health.

In summary, we establish feasibility of MenoLife to capture RWD as evidenced by the accumulation of self-reported metrics from 15,703 users, who reported 58,636 symptoms and 53,589 check-ins. We further demonstrate efficacy of a nutritional, synbiotic intervention to alleviate menopausal conditions from RWE. There was a statistically significant reduction in symptoms reporting when comparing Product Takers (PT) to Product non-Takers (PnT) for the most highly reported menopausal symptoms. Salient findings also include a reduction in daily reports of hot flashes (92% in 85% of PT participants), headaches (67% in 65% of PT participants) and mood swings (80% reduction in 70% of PT participants). We also observed a reduction in weekly reports of insomnia by 46% in 85% of PT participants and night sweats by 25% in 80% of PT participants. Consistent with the initiation of a gut-based intervention (synbiotic), 95% of the PT population reported a 17% increase in bloating. We further addressed the overall impact of MenoLabs synbiotics on mood and weight through a unique check-in prompt. We introduce the metric of Mood Boost as a method to quantitatively assess the subjective feeling of mood. Using this measure, PT reported a 71% increase in Mood Boost. Over a 10 week window of user-reported weight data, 27% of PT experienced a 6-7% decrease in body weight, with only 9% of the PnT cohort experiencing the same results. Importantly, only PT participants reported weight loss over 9%. Finally, we contend that MenoLife facilitates rapid and robust collection of RWD with significant granularity and a platform for scalability, providing the critical foundation for precision approaches in a long ignored menopausal population.